ABBV
Price
$171.09
Change
-$0.00 (-0.00%)
Updated
Nov 12 closing price
76 days until earnings call
MRK
Price
$98.58
Change
-$0.00 (-0.00%)
Updated
Nov 12 closing price
83 days until earnings call
Ad is loading...

ABBV vs MRK

Header iconABBV vs MRK Comparison
Open Charts ABBV vs MRKBanner chart's image
ABBVIE
Price$171.09
Change-$0.00 (-0.00%)
Volume$10.56M
CapitalizationN/A
Merck & Co
Price$98.58
Change-$0.00 (-0.00%)
Volume$12.28M
CapitalizationN/A
ABBV vs MRK Comparison Chart
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MRK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ABBV vs. MRK commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Buy and MRK is a Buy.

COMPARISON
Comparison
Nov 14, 2024
Stock price -- (ABBV: $170.35 vs. MRK: $98.50)
Brand notoriety: ABBV and MRK are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 156% vs. MRK: 91%
Market capitalization -- ABBV: $322.43B vs. MRK: $331.75B
ABBV [@Pharmaceuticals: Major] is valued at $322.43B. MRK’s [@Pharmaceuticals: Major] market capitalization is $331.75B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 4 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).

  • ABBV’s FA Score: 4 green, 1 red.
  • MRK’s FA Score: 2 green, 3 red.
According to our system of comparison, ABBV is a better buy in the long-term than MRK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 5 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s).

  • ABBV’s TA Score: 5 bullish, 5 bearish.
  • MRK’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, MRK is a better buy in the short-term than ABBV.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а -15.33% price change this week, while MRK (@Pharmaceuticals: Major) price change was -2.21% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -3.16%. For the same industry, the average monthly price growth was -4.10%, and the average quarterly price growth was +3.76%.

Reported Earning Dates

ABBV is expected to report earnings on Jan 29, 2025.

MRK is expected to report earnings on Feb 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-3.16% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRK($332B) and ABBV($322B) have the same market capitalization . MRK has higher P/E ratio than ABBV: MRK (935.64) vs ABBV (66.46). ABBV YTD gains are higher at: 13.943 vs. MRK (-7.846). ABBV has higher annual earnings (EBITDA): 17.2B vs. MRK (6.91B). ABBV has more cash in the bank: 12.8B vs. MRK (7.09B). MRK has less debt than ABBV: MRK (35.1B) vs ABBV (59.4B). MRK has higher revenues than ABBV: MRK (60.1B) vs ABBV (54.3B).
ABBVMRKABBV / MRK
Capitalization322B332B97%
EBITDA17.2B6.91B249%
Gain YTD13.943-7.846-178%
P/E Ratio66.46935.647%
Revenue54.3B60.1B90%
Total Cash12.8B7.09B180%
Total Debt59.4B35.1B169%
FUNDAMENTALS RATINGS
ABBV vs MRK: Fundamental Ratings
ABBV
MRK
OUTLOOK RATING
1..100
5553
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
12
Undervalued
PROFIT vs RISK RATING
1..100
638
SMR RATING
1..100
1928
PRICE GROWTH RATING
1..100
5963
P/E GROWTH RATING
1..100
2198
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRK's Valuation (12) in the Pharmaceuticals Major industry is in the same range as ABBV (17). This means that MRK’s stock grew similarly to ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is in the same range as MRK (38). This means that ABBV’s stock grew similarly to MRK’s over the last 12 months.

ABBV's SMR Rating (19) in the Pharmaceuticals Major industry is in the same range as MRK (28). This means that ABBV’s stock grew similarly to MRK’s over the last 12 months.

ABBV's Price Growth Rating (59) in the Pharmaceuticals Major industry is in the same range as MRK (63). This means that ABBV’s stock grew similarly to MRK’s over the last 12 months.

ABBV's P/E Growth Rating (21) in the Pharmaceuticals Major industry is significantly better than the same rating for MRK (98). This means that ABBV’s stock grew significantly faster than MRK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVMRK
RSI
ODDS (%)
Bullish Trend 1 day ago
55%
Bullish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 2 days ago
56%
Momentum
ODDS (%)
Bearish Trend 1 day ago
46%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
50%
Bearish Trend 2 days ago
43%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
48%
Bearish Trend 2 days ago
49%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
51%
Bearish Trend 2 days ago
43%
Advances
ODDS (%)
Bullish Trend 14 days ago
57%
Bullish Trend 6 days ago
48%
Declines
ODDS (%)
Bearish Trend 1 day ago
44%
Bearish Trend 2 days ago
49%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
46%
Bullish Trend 2 days ago
64%
Aroon
ODDS (%)
Bearish Trend 1 day ago
55%
Bearish Trend 2 days ago
43%
View a ticker or compare two or three
Ad is loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MRK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IDXX429.953.84
+0.90%
IDEXX Laboratories
RDN34.49-0.11
-0.32%
Radian Group
OMCL47.81-1.08
-2.21%
Omnicell
TRUE4.14-0.17
-3.94%
TrueCar
VRCA0.84-0.08
-8.37%
Verrica Pharmaceuticals

ABBV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABBV
1D Price
Change %
ABBV100%
-0.43%
PFE - ABBV
54%
Loosely correlated
+2.02%
JNJ - ABBV
36%
Loosely correlated
+0.39%
BMY - ABBV
32%
Poorly correlated
-1.03%
MRK - ABBV
31%
Poorly correlated
-0.08%
AMGN - ABBV
29%
Poorly correlated
+0.87%
More